Recent news on Abelcet

FDA raps Enzon on drug ads  -  25 May 2007
Trenton Times,..."The flash card is misleading because it presents unsubstanti ated superiority claims and overstates the efficacy of Abelcet," wrote Thomas Abrams,

Enzon Announces Timing of Annual Meeting of Shareholders  -  Apr 24, 2007
Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several

FDA Grants Full Approval for DepoCyt ® for the Treatment of ...  -  Apr 20, 2007
Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and DepoCyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
Business Wire (press release),Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and DepoCyt® in the United States. In addition, Enzon also receives royalties on sales

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
PharmaLive.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),For 2007, Enzon also expects continued stability of revenues from its Products segment as Oncaspar growth helps offset the Abelcet competitive challenges.

Zacks Bull and Bear of the Day Highlights: Chesapeake Energy ...  -  Feb 21, 2007
Business Wire (press release),Key product Abelcet sales continued to deteriorate in the fourth quarter of 2006. Further, another major source of revenue, Royalty, began to decline in the

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Genetic Engineering News (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

Risa Bernstein, Agency Co-Founder, Returns to Flashpoint Medica  -  Jan 17, 2007
PharmaLive.com (press release),Enzon for Abelcet, an IV anti-fungal agent, Novogyne (Noven and Novartis) for Vivelle Dot (estradiol transdermal system), a hormone replacement patch,

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
American Digital Networks (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business New Jersey (subscription),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Zacks Bull and Bear of the Day Highlights: Hittite Microwave ...  -  Jan 8, 2007
American Digital Networks (press release),Key product Abelcet sales continued to deteriorate for the third time in 2006. Although Royalty on PEG-Intron in the third quarter grew by 21% on a year

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional